Sandbox Reserved 1735
From Proteopedia
(Difference between revisions)
												
			
			| Line 24: | Line 24: | ||
==Protease Inhibitors for HIV-1 Treatment==  | ==Protease Inhibitors for HIV-1 Treatment==  | ||
| + | |||
| + | For HIV-1, protease inhibition is one method of five methods for controlling HIV-1. The HIV-1 protease protein is encoded within the pol gene. This gene holds the information for the replication of HIV. This means that the gene holds HIV-1 protease, as well as reverse transcriptase and integrase proteins (Blassel et. al, 2021). HIV-1 protease inhibitors are a method of treatment for HIV-1. However, HIV-1 protease inhibitors can lead to mutations within an individual and this is why they are classified as a treatment, but not a control. It is a constant chase to find which PR inhibitor works for a patient, and for how long it will work (Blassel et. al, 2021). HIV-1 protease inhibitors work by binding to the protease to prevent the protease from breaking down proteins. (López-Otín et. al, 2008).  | ||
==Protease Inhibitors for HIV-2 Treatment==  | ==Protease Inhibitors for HIV-2 Treatment==  | ||
Revision as of 04:55, 15 November 2022
| This Sandbox is Reserved from August 30, 2022 through May 31, 2023 for use in the course Biochemistry I taught by Kimberly Lane at the Radford University, Radford, VA, USA. This reservation includes Sandbox Reserved 1730 through Sandbox Reserved 1749. | 
 To get started:
 More help: Help:Editing  | 
HIV-1 Protease
  | |||||||||||
